Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Depreciation & Amortization (CF) rose 4597.51% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 3267.11%. This contributed to the annual value of $7.2 million for FY2024, which is 4605.58% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.7 million, which was up 4597.51% from $2.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $2.7 million during Q3 2025, with a 5-year trough of $700000.0 in Q1 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $1.2 million in 2023 and averaged $1.4 million.
  • In the last 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) soared by 60000.0% in 2021 and then soared by 1100.0% in 2023.
  • Rocket Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $1.0 million in 2021, then rose by 5.77% to $1.1 million in 2022, then increased by 26.91% to $1.4 million in 2023, then surged by 30.52% to $1.8 million in 2024, then surged by 48.3% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.5 million for Q1 2025.